Stories of Interest in 2012
As we bring 2012 to a close, we're looking back at a few of the interesting events that took place. It was a challenge to whittle this down to a…
Menu
Radio Silence: Three Reasons Why It Happens in BD
Consider the following situation: You are out-licensing an innovative asset in a niche therapeutic area It is a first-in-class molecule It has successfully demonstrated efficacy in two international Phase…
Geographic Diversity at BIO Europe 2012
As we've done in the past, we've tabulated the countries of origin from the stack of business card collected at BIO Europe 2012. Our "rules" for this analysis are simple.…
BIOEurope 2012: Does size matter?
We’ve returned from BIO Europe 2012 in Hamburg with a stack of business cards, pages of meeting notes, prioritized follow ups, and some great memories. We managed to completely fill…
Repositioned Drugs Surpass New Brands
There are some very interesting data published yesterday on FDA approval statistics: It was in 1984 when FDA first added the 505(b)(2) pathway for drug approval, a hybrid between the…
More Me-Too Products, Not Fewer
An article by our good friend Derek Hennecke in the September issue of Drug Development & Delivery really struck a nerve with us...but in a good way. To quote (with…
Pricing as a product differentiator
A recent article in Forbes by ex-Pfizer President or R&D John LaMattina asks a provocative question: Will Pricing Be a Key Differentiator For New Drugs? I recall some 10-15 years…
Observations from BIO 2012
As with BIO 2011, the bulk of our time was spent in the One-on-One Partnering sessions. More general reviews are found here, here, and here. As usual, BIO put on…
Unmeet needs should drive drug development, not money
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
Burrill Speaks, We Agree
The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…